These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11101198)

  • 21. Morning increase in ambulatory ischemia in patients with stable coronary artery disease. Importance of physical activity and increased cardiac demand.
    Parker JD; Testa MA; Jimenez AH; Tofler GH; Muller JE; Parker JO; Stone PH
    Circulation; 1994 Feb; 89(2):604-14. PubMed ID: 8313548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability.
    Acanfora D; Trojano L; Gheorghiade M; Picone C; Papa A; Furgi G; Giuliano F; Maestri R; Rengo F
    Am J Ther; 2002; 9(5):444-53. PubMed ID: 12237738
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
    Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hypertension associated with stable angina pectoris: favourable interaction between new metoprolol formulation (OROS) and nifedipine.
    Di Somma S; de Divitiis M; Bertocchi F; Carotenuto A; Cudemo G; Petitto M; Napodano M; de Divitiis O
    Cardiologia; 1996 Jul; 41(7):635-43. PubMed ID: 8831181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
    Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
    Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol.
    Hassager C; Thygesen K; Grande P; Fischer Hansen J; Mickley H; Gustafsson I; Skagen K; Steensgaard-Hansen F
    Cardiology; 2001; 96(2):65-71. PubMed ID: 11740134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective L-type, T-type, and nonspecific calcium-channel blockers for stable angina pectoris.
    Thadani U
    Am Heart J; 2002 Jul; 144(1):8-10. PubMed ID: 12094182
    [No Abstract]   [Full Text] [Related]  

  • 28. Circadian variations in ischemic threshold and their relation to the occurrence of ischemic episodes.
    Benhorin J; Banai S; Moriel M; Gavish A; Keren A; Stern S; Tzivoni D
    Circulation; 1993 Mar; 87(3):808-14. PubMed ID: 8095188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I; Charlon V; Lindberg E; Pordy R
    Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Felodipine and amlodipine in stable angina pectoris: results of a randomized double-blind crossover trial.
    Koenig W; Höher M
    J Cardiovasc Pharmacol; 1997 Apr; 29(4):520-4. PubMed ID: 9156363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris.
    Brogden RN; Markham A
    Drugs; 1997 Nov; 54(5):774-93. PubMed ID: 9360062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of amlodipine and isosorbide dinitrate on exercise-induced and ambulatory ischemia in patients with chronic stable angina pectoris.
    Steffensen R; Melchior T; Bech J; Nissen H; Haastrup B; Grande P; Rasmussen V; Hansen JF; Skagen K; Haghfelt T
    Cardiovasc Drugs Ther; 1997 Nov; 11(5):629-35. PubMed ID: 9493700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative effect of anti-anginal drugs on myocardial ischemia in patient with effort angina: evaluation by ambulatory electrocardiographic monitoring].
    Suzuki Y
    Hokkaido Igaku Zasshi; 1991 Jul; 66(4):441-9. PubMed ID: 1680782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats.
    Sandmann S; Min JY; Meissner A; Unger T
    Cardiovasc Res; 1999 Oct; 44(1):67-80. PubMed ID: 10615391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease.
    Panza JA; Diodati JG; Callahan TS; Epstein SE; Quyyumi AA
    J Am Coll Cardiol; 1992 Nov; 20(5):1092-8. PubMed ID: 1401608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats.
    Sandmann S; Spitznagel H; Chung O; Xia QG; Illner S; Jänichen G; Rossius B; Daemen MJ; Unger T
    Cardiovasc Res; 1998 Aug; 39(2):339-50. PubMed ID: 9798519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of propranolol, diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. Differential effects on ambulatory ischemia, exercise performance, and anginal symptoms. The ASIS Study Group.
    Stone PH; Gibson RS; Glasser SP; DeWood MA; Parker JD; Kawanishi DT; Crawford MH; Messineo FC; Shook TL; Raby K
    Circulation; 1990 Dec; 82(6):1962-72. PubMed ID: 2122926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of von Willebrand factor level and heart rate changes in acute coronary syndromes: a comparison with chronic ischemic conditions.
    Heper G; Bayraktaroğlu M
    Angiology; 2003; 54(3):287-99. PubMed ID: 12785021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
    Bernink PJ; Prager G; Schelling A; Kobrin I
    Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.